# Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

Source: https://onco.cc/trials/nct07192432/  
OnCo record `nct07192432` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Dose Level 1, VNX-202 in advanced solid tumours, run by Vironexis Biotherapeutics Inc., now recruiting.

## Summary

Gene Therapy for HER-Positive Cancer (SENTRY-HER2) is a phase 1/2 interventional study registered as NCT07192432 by Vironexis Biotherapeutics Inc., with 27 participants planned, started 2025-11-18 and due to reach its primary completion in 2033-09. Interventions recorded: Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202 and Dose Level 4, VNX-202.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07192432
- Phase: 1/2
- Setting: A Phase 1/2, First-in-Human Study of VNX-202 Gene Therapy in Patients With HER2-Positive Cancer
- Sponsor: Vironexis Biotherapeutics Inc.
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT07192432: https://clinicaltrials.gov/study/NCT07192432

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07192432.json